Aim: The purpose of this study is to evaluate the efficacy of TLV for the initially hospitalized
patients with ADHF. Methods: From 2011 to 2013, consecutive 124 patients initially hospitalized with a diagnosis
of ADHF (clinical scenario 2/5) at Nagoya Heart Center. They were treated with or
without TLV (TLV (−); n = 81, TLV (+); n = 43). We retrospectively analyzed the clinical
outcome of these patients. Results: The results are shown in the Table 1 and Fig. 1. 39.5% of cases were re-hospitalized.
In the re-hospitalized cases, the incidence of WRF was significantly higher. Conclusion: the treatment with tolvaptan could shortened the duration of bed-rest and prevent
WRF and re-hospitalization. The results of this study suggest tolvaptan initiated
for acute treatment of patients initially hospitalized with ADHF had effect outcome
in daily clinical practice.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
